Peter Park

Peter Park, PhD

Professor of Biomedical Informatics
Director, Bioinformatics and Integrative Genomics (BIG) PhD Track

10 Shattuck Street, Boston, MA 02115

Dr. Park is a Professor of Biomedical Informatics at Harvard Medical School and the director of its Bioinformatics and Integrative Genomics PhD program. His research group specializes in computational and statistical analysis of large-scale DNA sequencing data to understand genetic and epigenetic mechanisms related to disease processes. Originally trained in applied mathematics (B.A., Harvard; Ph.D., Caltech), he was introduced to molecular biology and genetics during his postdoctoral studies in biostatistics. His laboratory has developed several algorithms for identifying and interpreting genomic alterations in the human genome, especially those from cancer patients. His group has made major contributions to many consortium projects such as The Cancer Genome Atlas (TCGA), Encyclopedia of DNA Elements (ENCODE), and Brain Somatic Mosaicism Network, and 4D Nucleome, and Somatic Mosaicism across Human Tissues (SMaHT). His work has been funded by the National Institutes of Health, Cancer Research UK Grand Challenges, The Mark Foundation for Cancer Research, Simons Foundation, Chan Zucherberg Initiative, Blavatnik Therapeutics Challenge, the HMS Quadrangle Fund for Advancing and Seeding Translational Research (Q-FASTR), and others.


DBMI Research Areas
DBMI Courses
Somatic mutations and single-nucleus transcriptomics reveal uniquely human properties of neuronal aging.
Authors: Caglayan E, Lamba I, Devi MM, Finander B, Luquette LJ, Exposito-Alonso D, Zhao S, Jin B, Miller MB, Park PJ, Sherwood CC, Walsh CA.
bioRxiv
View full abstract on Pubmed
Correlation-aware discovery of co-occurring mutational signatures in cancer.
Authors: Jin H, Geiger B, Glodzik D, Gulhan DC, Park PJ.
bioRxiv
View full abstract on Pubmed
Discovery of BMS-986449: A Potent, Selective Degrader of the Transcription Factors IKZF2 (Helios) and IKZF4 (Eos) to Target Regulatory T Cells in Solid Tumors.
Authors: Cherney EC, Nair SK, Penmetsa SBVK, Shimpukade B, Huang A, Bilder D, Degnan AP, Kumi GK, Zhang L, Purandare AV, Yang F, Li G, Shan W, Chen Y, Lin S, Park P, Dodd DS, Kantheti D, Padamata S, Manepalli RKVLP, Sirigireddy NMR, Malappa M, Murali Dhar TG, Cavallaro CL, Li L, Oderinde MS, Smith D, Pawluczyk JM, Kempson J, Vetrichelvan M, Gupta A, Mathur A, Rampulla R, Weigelt CA, Lakkaraju SK, Khandelwal P, Katepalli M, Lenin TNK, Riedmaier S, DiPetrillo K, Foster KA, Rayeni MK, Choure V, Das T, Levine S, Kwok M, Cvijic ME, Li X, Fang H, Tagore DM, Ravindran MS, Gujaran SR, Natarajan A, Zhu J, Pagarigan B, Srinivas P, Salinger A, Dongre AR, Bell-Temin H, Pham H, Desai PR, Calder O, Shi L, Guo S, Khambatta G, Sivakumar P, Ladygina N, Narla RK, Dhar G, Anandam A, Khanna V, Dudhgaonkar S, Liu J, Barnes MJ, Borzilleri R, Lombardo LJ, Vite G, Hunt JT, Balog A.
J Med Chem
View full abstract on Pubmed
Recurrent patterns of TOP1-mediated neuronal genomic damage shared by major neurodegenerative disorders.
Authors: Zhou Z, Luquette LJ, Dong G, Kim J, Ku J, Kim K, Ramesh N, Bae M, Caplin A, Shao DD, Sahile B, Essuman K, Goodman E, Miller MB, Huang AY, Nathan WJ, Nussenzweig A, Park PJ, Lagier-Tourenne C, Lee EA, Walsh CA.
Cell
View full abstract on Pubmed
The Role of Germline Transposable Element Insertions in Pediatric Cancer Predisposition.
Authors: Sexton CE, Hamilton KV, Chu C, Ting DT, Garber JE, Park PJ, Kamihara J.
Cancer Res Commun
View full abstract on Pubmed
Intranasal CRISPR lipid nanoparticles targeting MAPK9 attenuate neuroinflammation after traumatic brain injury.
Authors: Kara G, Holcomb M, Hijazi AA, Ali Y, López-Espinosa J, Cruz-Pineda L, Park P, Flinn H, Taylor N, Galbraith T, McMahon L, Rostomily R, Leonard F, Villapol S.
Biomed Microdevices
View full abstract on Pubmed
Reply: Genetically proxied GLP1R expression does not predict exenatide response in the Exenatide-PD3 trial.
Authors: Woo KA, Jang Y, Kim HJ, Park PJ.
Brain
View full abstract on Pubmed
Intranasal CRISPR-lipid nanoparticles targeting MAPK9 reduce neuroinflammation after traumatic brain injury.
Authors: Kara G, Ali Y, López-Espinosa J, Park P, Holcomb M, Flinn H, Taylor N, Galbraith T, Leonard F, Villapol S.
bioRxiv
View full abstract on Pubmed
Topographical archetypes of somatic mutagenesis in cancer.
Authors: Lynch AW, Lee SS, Hummel JP, Geiger B, Lawrence MS, Jin H, Gulhan DC, Park PJ.
bioRxiv
View full abstract on Pubmed
A recurrent sequencing artifact on Illumina sequencers with two-color fluorescent dye chemistry and its impact on somatic variant detection.
Authors: Fu BJ, Viswanadham VV, Maziec D, Jin H, Park PJ.
Genome Biol
View full abstract on Pubmed